Since it has been described that a population of CD5+ B cells can produce “natural” antibodies, mainly of IgM isotype, potentially reactive with solid tumor cells [28], [29], we investigated whether the IgM fraction of BM plasma contain antibodies reacting with leukemic cells in CML. The gene discussed is CD5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.